Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats

被引:25
作者
Walf, Alicia A. [1 ]
Frye, Cheryl Anne [1 ,2 ,3 ,4 ]
机构
[1] SUNY Albany, Dept Psychol, Albany, NY 12222 USA
[2] SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA
[3] SUNY Albany, Ctr Neurosci, Albany, NY 12222 USA
[4] SUNY Albany, Ctr Life Sci Res, Albany, NY 12222 USA
来源
BEHAVIOURAL PHARMACOLOGY | 2010年 / 21卷 / 03期
关键词
DMBA; estrogen receptor; lordosis; selective estrogen receptor modulator; tumor; ESTROGEN-RECEPTOR MODULATORS; INDUCED MAMMARY-TUMORS; QUALITY-OF-LIFE; BREAST-CANCER; POSTMENOPAUSAL WOMEN; BETA; EXPRESSION; RISK; MECHANISMS; TAMOXIFEN;
D O I
10.1097/FBP.0b013e32833a5cb0
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Controversy surrounds the efficacy and safety of 17 beta-estradiol (E-2)-mimetic therapies to women for treatment of menopausal symptoms. An important question is the nature of the trophic actions of E-2-mimetics in the brain for behavioral processes versus in the periphery for beneficial effects related to osteoporosis, or unwanted proliferative effects in the reproductive tissues, such as mammary glands and uterus. Of recent interest are the effects of selective estrogen receptor modulators, which can have tissue specific actions, for these processes. In the present study, the effects were determined of E-2 alone, or co-administered with a selective estrogen receptor modulator, raloxifene, for anxiety-like, depression-like, and trophic peripheral effects in ovariectomized rats that were exposed to a chemical carcinogen (7,12-dimethylbenz(a) anthracene), or not. Once per week, rats were administered vehicle, E-2 (0.09 mg/kg) and/or raloxifene (1 mg/kg) subcutaneously 44-48 h before testing in a positive control, E-2-dependent behavior (lordosis), depression (forced swim test), and anxiety (elevated plus maze) behavioral assays. In addition to behavioral endpoints, incidence and number of tumors, and tumor, pituitary gland, and uterine weight 14 weeks after carcinogen-exposure, and weekly hormone treatments, were analyzed. Rats administered 7,12-dimethylbenz(a) anthracene had an increased number and size of tumors, compared with vehicle treatment. E-2 + raloxifene increased the number of tumors. Administration of E-2 or E-2 + raloxifene, but not raloxifene alone, increased pituitary and uterine weight, compared with vehicle administration. E-2 or E-2 + raloxifene, but not raloxifene alone, also increased the incidence of lordosis and reduced the depression-like behavior in the forced swim test (i.e. decreased time spent immobile) compared with vehicle administration. However, administration of E-2 or raloxifene reduced anxiety behavior in the elevated plus maze (i.e. increased time spent on the open arms of the maze), compared with vehicle treatment. Together these data show that E-2 and/or raloxifene can have some effects to alter the behavior of ovariectomized rodents, depending upon the task. As well, E-2, with or without raloxifene, can also have clear trophic actions in peripheral tissues, such as carcinogen-induced tumors, uterus, and pituitary glands. Behavioural Pharmacology 21: 231-240 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:231 / 240
页数:10
相关论文
共 62 条
[1]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[2]   Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats [J].
Berendsen, HHG ;
Weekers, AHJ ;
Kloosterboer, HJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 419 (01) :47-54
[3]   Menopausal Hormone Therapy [J].
Bhavnani, Bhagu R. ;
Strickler, Ronald C. .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2005, 27 (02) :137-162
[4]   Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene [J].
Callejo, J ;
Cano, A ;
Medina, M ;
Villaronga, M ;
Gonzalez-Bosquet, E ;
Sabria, J ;
Lailla, JM .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (05) :601-608
[5]  
Cheung SY, 2003, INT J ONCOL, V22, P1383
[6]   THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN [J].
COLDITZ, GA ;
HANKINSON, SE ;
HUNTER, DJ ;
WILLETT, WC ;
MANSON, JE ;
STAMPFER, MJ ;
HENNEKENS, C ;
ROSNER, B ;
SPEIZER, FE .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (24) :1589-1593
[7]   The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].
Cummings, SR ;
Eckert, S ;
Krueger, KA ;
Grady, D ;
Powles, TJ ;
Cauley, JA ;
Norton, L ;
Nickelsen, T ;
Bjarnason, NH ;
Morrow, M ;
Lippman, ME ;
Black, D ;
Glusman, JE ;
Costa, A ;
Jordan, VC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197
[8]   Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain [J].
Cyr, M ;
Thibault, C ;
Morissette, M ;
Landry, M ;
Di Paolo, TS .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (02) :242-257
[9]   Estrogenic activity of tamoxifen and raloxifene on rat brain AMPA receptors [J].
Cyr, M ;
Morissette, M ;
Landry, M ;
Di Paolo, T .
NEUROREPORT, 2001, 12 (03) :535-539
[10]   Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].
Delmas, PD ;
Bjarnason, NH ;
Mitlak, BH ;
Ravoux, AC ;
Shah, AS ;
Huster, WJ ;
Draper, M ;
Christiansen, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647